First Time Loading...
B

Beijing Leadman Biochemistry Co Ltd
SZSE:300289

Watchlist Manager
Beijing Leadman Biochemistry Co Ltd
SZSE:300289
Watchlist
Price: 4.7 CNY 1.73% Market Closed
Updated: May 17, 2024

Profitability Summary

44/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Beijing Leadman Biochemistry Co Ltd

Revenue
448m CNY
Cost of Revenue
-205.7m CNY
Gross Profit
242.3m CNY
Operating Expenses
-245.3m CNY
Operating Income
-3m CNY
Other Expenses
7.3m CNY
Net Income
4.3m CNY

Margins Comparison
Beijing Leadman Biochemistry Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Beijing Leadman Biochemistry Co Ltd
SZSE:300289
2.6B CNY
54%
-1%
1%
US
Abbvie Inc
NYSE:ABBV
290.3B USD
66%
30%
9%
US
Amgen Inc
NASDAQ:AMGN
168.9B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD
87%
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.7B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
138.6B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
84.6B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
50.9B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
33.5B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
40T KRW
48%
30%
25%
Country CN
Market Cap 2.6B CNY
Gross Margin
54%
Operating Margin
-1%
Net Margin
1%
Country US
Market Cap 290.3B USD
Gross Margin
66%
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 168.9B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 113.4B USD
Gross Margin
87%
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 106.7B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 138.6B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 84.6B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 50.9B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 33.5B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 40T KRW
Gross Margin
48%
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Beijing Leadman Biochemistry Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Beijing Leadman Biochemistry Co Ltd
SZSE:300289
2.6B CNY
0%
0%
0%
0%
US
Abbvie Inc
NYSE:ABBV
290.3B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
168.9B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.7B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
138.6B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
84.6B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
50.9B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
33.5B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
40T KRW
5%
4%
6%
4%
Country CN
Market Cap 2.6B CNY
ROE
0%
ROA
0%
ROCE
0%
ROIC
0%
Country US
Market Cap 290.3B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 168.9B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 113.4B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 106.7B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 138.6B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 84.6B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 50.9B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 33.5B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 40T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More